Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?  by Kernis, Steven J et al.
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OBJECTIVES We sought to determine if beta-blocker therapy improves clinical outcomes of acute
myocardial infarction (AMI) after successful primary percutaneous coronary intervention
(PCI).
BACKGROUND We have shown that pre-treatment with beta-blockers has a beneficial effect on short-term
clinical outcomes in patients undergoing primary PCI for AMI. It is unknown if beta-blocker
therapy after successful primary PCI improves prognosis of AMI.
METHODS We analyzed clinical, angiographic, and outcomes data in 2,442 patients who underwent
successful primary PCI in the Primary Angioplasty in Acute Myocardial Infarction-2
(PAMI-2), PAMI No Surgery-on-Site (PAMI noSOS), Stent PAMI, and Air PAMI trials.
We classified patients into beta group (those who received beta-blockers after successful PCI,
n  1,661) and no-beta group (n  781). We compared death and major adverse cardiac
events (MACE) (death, reinfarction, and ischemia-driven target vessel revascularization) at
six months between groups receiving and not receiving beta-blockers.
RESULTS At six months, beta patients were less likely to die (2.2% vs. 6.6%, p  0.0001) or experience
MACE (14 vs. 17%, p  0.036). In multivariate analysis, beta-blockers were independently
associated with lower six-month mortality (odds ratio [OR] 0.43, 95% confidence interval
[CI] 0.26 to 0.73, p  0.0016). Beta-blocker therapy was an independent predictor of lower
six-month events in high-risk subgroups: ejection fraction 50% (death: OR 0.34, 95% CI
0.19 to 0.60, p  0.0002) or multi-vessel coronary artery disease (CAD) (death: OR 0.26,
95% CI 0.14 to 0.48, p  0.0001; MACE: OR 0.57, 95% CI 0.41 to 0.80, p  0.0011).
CONCLUSIONS Treatment with beta-blockers after successful primary PCI is associated with reduced
six-month mortality, with the greatest benefit in patients with a low ejection fraction or
multi-vessel CAD. (J Am Coll Cardiol 2004;43:1773–9) © 2004 by the American College
of Cardiology FoundationP
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whe American College of Cardiology/American Heart As-
ociation guidelines recommend routine use of beta-
lockers after acute myocardial infarction (AMI) (1). This
ecommendation is based on results of studies performed in
he pre-fibrinolytic era (2–6) and in patients treated with
hrombolytics (7–11). In the era of primary angioplasty, no
linical trials have examined the independent impact of
See page 1788
eta-blockers on clinical outcomes after successful primary
ercutaneous coronary intervention (PCI) for AMI. Re-
ently, we reported improved short-term clinical outcomes
hen beta-blockers are given for AMI before primary PCI
12). We believe that the benefit from pre-treatment with
eta-blockers is likely due to attenuation of the harmful
nhanced sympathetic drive that causes tachycardia, hyper-
ension, and increased myocardial stress during AMI. It is
ess clear, however, if beta-blockade after successful primary
From the *Cardiology Division, William Beaumont Hospital, Royal Oak, Mich-
gan; and †Cardiology Division, Lenox Hill Hospital, New York, New York.
Manuscript received August 12, 2003; revised manuscript received September 19,
c003, accepted September 23, 2003.CI improves prognosis. To address this hypothesis, we
nalyzed patients enrolled in the Primary Angioplasty in
cute Myocardial Infarction-2 (PAMI-2), No Surgery-on-
ite (noSOS), Stent PAMI, and Air PAMI trials.
ETHODS
tudy population. We pooled clinical, angiographic, and
linical outcome data from 2,442 patients who underwent
uccessful primary PCI in the PAMI-2 (13,14), noSOS
15), Stent-PAMI (16,17), and Air-PAMI trials (18) (Ta-
le 1). The PAMI studies without data on post-PCI
eta-blocker use were not included. Successful PCI was
efined as achievement of Thrombolysis In Myocardial
nfarction (TIMI) 3 flow and final residual stenosis 50%
n the infarct-related artery (IRA). Left ventricular ejection
raction (LVEF) was determined by left ventriculography at
he time of emergent cardiac catheterization. We excluded
75 patients with unsuccessful PCI from the analysis. A
otal of 1,661 patients received post-procedural beta-
lockers, and 781 patients did not.
AMI study protocol. All patients enrolled presented
ithin 12 h of onset of chest pain and electrocardiographichanges (ST elevation in two contiguous leads or left bundle
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Beta-Blockers After Successful Primary Angioplasty May 19, 2004:1773–9ranch block). The trials excluded patients presenting with
ardiogenic shock, those with high bleeding risk, and those
ho did not give informed consent. Before PCI, patients
eceived 325 mg chewable aspirin, a 5,000- to 10,000-U bolus
f heparin, and nitroglycerin. Intravenous beta-blockers were
ecommended for all patients without contraindications in all
tudies. Patients were taken emergently to the cardiac cath lab
or coronary angiography and possible intervention. Those
atients deemed unlikely to benefit from primary PCI (IRA
ith 70% stenosis or supplying a small area of myocardium)
ere treated medically without mechanical intervention. Pa-
ients found to have unprotected left main stenosis 60% or
evere proximal three-vessel coronary artery disease (CAD)
nd spontaneous reperfusion were referred for coronary artery
ypass grafting (CABG). In the absence of these contraindi-
ations, patients underwent PCI. Patients undergoing PCI
ere given heparin to achieve an activated clotting time
etween 350 and 400 s. Study monitors recorded in-hospital
nd six-month follow-up events at each center from review of
atient medical records and, if indicated, telephone contact
ith the patient or family.
tudy outcome. We classified patients into beta group
those who received beta-blockers after successful PCI, n 
,661) and no-beta group (those who did not receive
eta-blockers after PCI, n  781). We compared baseline
linical and angiographic characteristics of both groups and
ssessed the incidence of death and major adverse cardiac
Abbreviations and Acronyms
AMI  acute myocardial infarction
CABG  coronary artery bypass grafting
CAD  coronary artery disease
IRA  infarct-related artery
I-TVR  ischemia driven target vessel revascularization
LVEF  left ventricular ejection fraction
MACE  major adverse cardiac events
PAMI  Primary Angioplasty in Acute Myocardial
Infarction
PCI  percutaneous coronary intervention
PVD  peripheral vascular disease
RCA  right coronary artery
TIMI  Thrombolysis in Myocardial Infarction
Table 1. PAMI Database
Study
Total
PCI*
PAMI-2 (1991–1993)
(randomized and registry)
880
Stent PAMI (1997–1998)
(randomized and registry)
1,290
PAMI NoSOS (1996–1998) 440
AirPAMI (1997–1999)
(randomized to transfer for PCI)
63
Total 2,917
Dates in parentheses indicate years of study enrollment. *
underwent PCI during index hospitalization. †Successful PC
stenosis 50% in the infarct-related artery. Numbers in parPAMI  Primary Angioplasty in Acute Myocardial Infarction;vents (MACE) (death, reinfarction, and ischemic-driven
arget vessel revascularization) at six months.
tatistics. Statistical analyses were completed on the cate-
orical variables using a chi-square test where appropriate
expected frequency 5); otherwise a Fisher exact test was
sed. Continuous variables were examined using a Wil-
oxon rank test. This is a nonparametric approximation of
he t test. Kaplan-Meier survival curves were created for the
umulative incidence for death at six months comparing
eta versus no-beta groups with a log-rank test.
A propensity score was derived using step-down logistic
egression analyses to determine predictors of beta-blocker
se after successful PCI. It adjusted for variables including
ge 70, history of peripheral vascular disease (PVD), final
RA percent stenosis, prior CABG, and having a right
oronary artery (RCA) infarct. This score was included
long with beta-blocker use in further multivariate analyses
o adjust for the likelihood that a given patient would
eceive beta-blockers post-PCI. The SAS version 8.0 (Cary,
orth Carolina) was used for all analyses.
To determine the independent correlation of beta-
locker use with death and MACE at six months, we
erformed step-down logistic regression analyses. Clinical
nd angiographic differences (age, gender, current smoker,
istory of diabetes, PVD or chronic obstructive lung disease,
rior angina, PCI, stent or CABG, Killip class 1, multi-
essel CAD, EF 50% [operator defined], final residual
tenosis, systolic blood pressure 100, or IRA in the left
ircumflex or RCA; p 0.10) and the propensity score were
sed as potential covariates in the models. Similar analyses
ere performed in the following subgroups: LVEF 50%,
 1,361; multi-vessel CAD, n  1,124; and those who
urvived index hospitalization without MACE, n  2,323.
ESULTS
eta-blocker use. Of the 2,442 patients who had success-
ul primary PCI, 1,661 patients (68%) were given beta-
lockers after PCI. Across the four PAMI studies, the
ercent of patients given beta-blockers post-PCI ranged
rom 53% (Air PAMI) to 82% (NoSOS).
ccessful
PCI†
Beta Group
(n  1,661)
No-Beta Group
(n  781)
30 (94%) 602 (73%) 228 (27%)
41 (88%) 344 (82%) 74 (18%)
18 (95%) 687 (60%) 454 (40%)
53 (84%) 28 (53%) 25 (47%)
42 (84%) 1,661 (68%) 781 (32%)
PCI indicates number of patients within each study that
defined as achievement of TIMI 3 flow and final residual
es indicate percent of PCI cases defined as successful.Su
8
1,1
4
2,4
Total
I was
enthes
PCI  percutaneous coronary intervention.
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May 19, 2004:1773–9 Beta-Blockers After Successful Primary Angioplastyaseline characteristics. Beta patients were younger; they
ess frequently had a history of prior angina, CABG, PCI,
iabetes, chronic obstructive lung disease (COPD), PVD,
r admission Killip class1; and they were more likely to be
aking beta-blockers before emergent cardiac catheteriza-
ion (Table 2). Patients receiving beta-blockers less com-
Table 2. Baseline Clinical Characteristics of St
Characteristics
Beta G
(n  1
Age (mean  SD) (yrs) 60 
Women 42
Heart rate* 88 
SBP* 109 
Diabetes mellitus 24
Ever smoker 1,11
Family history of CAD 408/1,15
Prior myocardial infarction 21
Prior angina 190/1,27
Prior PCI 146
Prior congestive heart failure 32
Prior CABG 40
Prior beta-blocker use† 561/1,28
Peripheral vascular disease 75/1,629
Hypertension 73
Hyperlipidemia 459/1,14
Stroke or TIA 73
Chronic obstructive lung disease 28/1,052
Killip class on admission
1 1,439
2 172
3 24
4 3
*Highest heart rate and lowest SBP recorded from presentat
†Beta-blocker use prior to initial emergent cardiac catheteriz
CABG  coronary artery bypass grafting; CAD  corona
 systolic blood pressure; TIA  transient ischemic attack.
Table 3. Baseline Angiographic Characteristics
Characteristics
Beta Group
(n  1,661
ER to balloon time (min)†
Mean  SD (median) 143  145 (11
Baseline TIMI flow
0 62.4%
1 10.8%
2–3 26.8%
Initial diameter stenosis (%) 98.0  4.7
LVEF (%) 49.2  12
EF  50% 39%
Infarct-related artery location‡
RCA 44.6%
LCX 13.5%
LAD 41.2%
LM 0.7%
SVG 0.06%
Stent implantation 38%
Final diameter stenosis (%) 12.7  12.1
*Operator-defined angiographic data were used for this a
department to the first balloon inflation. ‡Right coronary ar
(LAD), left main (LM), saphenous vein graft (SVG).LVEF  left ventricular ejection fraction; TIMI  Thrombolyonly had in-hospital sustained hypotension (4% in beta
roup vs. 8% in no-beta group, p  0.0004) and in-hospital
illip class 1 (7% in beta group vs. 10% in no-beta group,
 0.039), although in-hospital bradycardia occurred with
qual frequencies in both groups (2.6% in beta group vs.
.4% in no-beta group). Angiographically, the beta group
Groups
No-Beta Group
(n  781) p Value
62  12  0.0001
) 221 (28%) 0.12
88  21 0.70
110  24 0.83
) 138 (18%) 0.047
) 506 (65%) 0.26
) 219/605 (36%) 0.72
) 119 (15%) 0.13
) 124/662 (19%) 0.033
) 98 (13%) 0.0042
) 24 (3.1%) 0.074
) 43 (5.6%)  0.0001
) 197/680 (29%)  0.0001
) 59/755 (7.8%) 0.0015
) 365 (48%) 0.16
) 224/610 (37%) 0.17
) 44 (5.7%) 0.16
) 42/546 (7.7%)  0.0001
Killip  1
) 653 (84.8) 0.045
) 97 (12.6%)
) 17 (2.2%)
) 3 (0.4%)
emergency room until arrival in the cath lab is shown here.
ry disease; PCI  percutaneous coronary intervention; SBP
tudy Groups*
No-Beta Group
(n  781) p Value
143  203 (110)
0.17
67.1% TIMI 2–3, p  0.08
9.5%
23.5%
97.9  5.0 0.42
48.1  13 0.087
39% 0.996
38.2% 0.0028
16.5% 0.051
43.4% 0.30
0.4%
1.6%
35% 0.23
14.7  12.4 0.0001
. †Calculated as the time from arrival at the emergency
CA), left circumflex artery (LCX), left anterior descendingudy
roup
661)
12
1 (25%
20
26
3 (15%
1 (68%
5 (35%
7 (13%
0 (15%
(8.8%
(2.0%
(2.4%
9 (44%
(4.6%
1 (45%
5 (40%
(4.4%
(2.7%
(87.9%
(10.5%
(1.5%
(0.2%
ion to
ation.
ry arteof S
)
3)
nalysis
tery (Rsis In Myocardial Infarction.
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Beta-Blockers After Successful Primary Angioplasty May 19, 2004:1773–9ad a slightly lower final diameter stenosis and the IRA was
he RCA more frequently (Table 3).
he relation of beta-blocker use with six-month clinical
utcomes. Patients receiving beta-blocker therapy after
rimary PCI had lower six-month mortality (2.2% vs. 6.6%,
 0.0001) and MACE (14% vs. 17%, p  0.036)
ompared with patients without beta-blocker use (Fig. 1
nd Table 4). In survival analysis, six-month death and
ACE were lower in the beta group (log-rank p  0.0001
or death, p  0.12) (Fig. 2). After adjusting for baseline
linical and angiographic differences and propensity score,
tep-down multivariate Cox regression analyses showed that
eta-blocker use was a significant independent predictor of
ower six-month mortality (OR 0.43, 95% CI 0.26 to 0.73,
 0.0016), but not MACE (OR 0.87, 95% CI 0.66 to
.13, p  0.29). Other variables independently associated
ith increased six-month mortality included EF 50%,
ulti-vessel CAD, age, history of PVD, Killip class 1,
nd a non-RCA (Fig. 3).
ubset analysis. The protective effect of post-procedural
eta-blocker therapy was seen in patients with low EF
death: 2.6% vs. 8.2%, p  0.0001; MACE: 15% vs. 19%,
 0.12) and those with multi-vessel CAD (death: 2.7%
s. 10%, p  0.0001; MACE: 14% vs. 22%, p  0.0003),
igure 1. Six-month clinical outcomes of study groups. EF  ejection
raction; MACE  major adverse cardiac events; MVD  multi-vessel
isease; SVD  single-vessel disease.
Table 4. Comparison of Six-Month Clinical O
Outcome
Beta Grou
(n  1,661
Six-month outcomes
Death 36/1,644 (2.2
Reinfarction* 55/1,619 (3.4
Ischemia-driven TVR† 163/1,573 (10
MACE‡ 215 (14
*Recurrence of clinical symptoms (or the development of ne
creatine kinase and creatine kinase-MB enzyme levels. †Defi
target vessel prompted by symptoms or objective evidence
ischemic-driven TVR.MACE  major adverse cardiac event; TVR  target vessel reut not in those with EF 50% (death: 1.3% vs. 1.5%, p 
.00; MACE: 11% vs. 11%, p 0.95) or single-vessel CAD
death: 1.8% vs. 2.9%, p 0.20; MACE: 14% vs. 11%, p
.28) (Fig. 1). After excluding patients with in-hospital
ACE beta group, n  1,562; no-beta group, n  727),
eta patients (all patients included) were less likely to die at
ix months (1.0% vs. 2.1%, p  0.042) and had a trend
oward lower MACE (9% vs. 11%, p  0.10) (Fig. 1).
atients receiving beta-blockers had higher survival and
ACE-free survival at six months (Fig. 2).
In patients with EF50%, beta-blockers were significant
ndependent predictors of lower six-month mortality (OR
.34, 95% CI 0.19 to 0.60, p  0.0002) but not MACE
OR 0.80, 95% CI 0.58 to 1.10, p  0.17). In patients with
ulti-vessel CAD, beta-blockers were significant indepen-
ent predictors of lower six-month mortality (OR 0.26, 95%
I 0.14 to 0.48, p  0.0001) and MACE (OR 0.57, 95%
I 0.41 to 0.80, p  0.0011). Beta-blocker therapy had a
odest but nonsignificant independent effect on six-month
linical outcomes in patients who survived the index hospi-
alization without MACE (death: OR 0.58, 95% CI 0.29 to
.17, p  0.13; MACE: OR 0.80, 95% CI 0.59 to 1.10, p
0.17).
ISCUSSION
eta-blocker therapy imparts a significant six-month mor-
ality benefit when given to AMI patients after successful
rimary PCI. Beta-blockade was associated with an absolute
isk reduction of 4.4% in six-month mortality (2.2% in beta
roup vs. 6.6% in no-beta group); indicating that treating 23
atients prevented one death at six months. Previous large-
cale trials have also demonstrated reductions in mortality
ith beta-blocker therapy before and after primary fibrino-
ysis in the management of AMI. Teo et al. (7) reported a
.2% absolute risk reduction (5.4% with beta-blockers vs.
.6% without beta-blockers), which translates into one life
aved per 83 patients treated. In multivariate analyses,
eta-blockers were independently associated with lower
ortality. We believe that our study is the first to show
ignificant benefit from beta-blocker therapy even after
uccessful primary angioplasty.
Further analyses revealed that two patient subgroups
rove this benefit: patients with EF50% and patients with
mes Between Study Groups
No-Beta Group
(n  781) p Value
51/775 (6.6%)  0.0001
24/759 (3.2%) 0.77
70/720 (9.7%) 0.64
124 (17%) 0.036
trocardiographic changes) accompanied by new elevation of
either percutaneous reintervention or bypass surgery on the
chemia. ‡Composite end point of death, reinfarction, orutco
p
)
%)
%)
.4%)
%)
w elec
ned as
of isvascularization.
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May 19, 2004:1773–9 Beta-Blockers After Successful Primary Angioplastyulti-vessel CAD. Six-month mortality and MACE were
ower in beta patients in each of these subgroups. In patients
ith low EF an absolute risk reduction of 5% for six-month
ortality and 4% for six-month MACE was seen from
eta-blocker therapy. In patients with multi-vessel CAD,
bsolute risk reductions of 7.3% for six-month mortality and
% for six-month MACE were observed from beta-blocker
herapy. Interestingly, these are larger reductions than the
.8% absolute risk reduction in one-year mortality reported
n a recent meta-analysis of beta-adrenergic blocker therapy
or New York Heart Association functional class II and III
ongestive heart failure patients (19).
This significant mortality reduction in patients with
ither reduced EF or multi-vessel CAD is not surprising.
ultiple large trials, including the meta-analysis by Brophy
Figure 2. Six-month mortality survival curves bt al. (19), have documented improvement in clinical out- womes seen with beta-adrenergic blockade in patients with
eft ventricular systolic dysfunction, with or without con-
estive heart failure (11,20). The data on beta-blockers in
atients with multi-vessel versus single-vessel CAD, how-
ver, are less well established. Given their well-documented
nti-ischemic and antiarrhythmic properties, beta-blockers
ight be expected to improve clinical outcomes across all
hese subgroups, especially with multi-vessel CAD where
ntreated coronary lesions in non-infarct-related arteries
emain.
Patients with normal EF and those with single-vessel
AD showed no statistically significant reduction in six-
onth mortality or MACE with post-PCI beta-blockade,
lthough mortality reduction may be clinically significant in
atients with single-vessel CAD (1.8% vs. 2.9%). Given the
en study groups. Abbreviations as in Figure 1.etweealth of data supporting beneficial effects of beta-blockers
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Beta-Blockers After Successful Primary Angioplasty May 19, 2004:1773–9n long-term clinical outcomes, this observation may be at
dds with intuitive expectation. However, no previous
imilar studies analyzed this large subgroup of AMI patients
reated successfully with primary PCI. It is enticing to
peculate that complete and successful primary revascular-
zation early in the course of AMI in patients with normal
VEF reduces their future risk of cardiac events to a point
here chronic beta-blockade becomes unnecessary. Al-
hough our retrospective study does not allow such a
onclusion to be made definitively, we find this possibility
ntriguing.
It is possible that the improved prognosis seen in beta
atients was in large part due to a selection bias favoring use
f beta-blockers in healthier patients (those with less fre-
uent histories of CAD, chronic obstructive lung disease,
nd diabetes). Patients with sustained hypotension, CHF,
nd bradycardia during the index hospitalization, for exam-
le, are generally not treated with beta-blockers. In fact, we
id find that a lower percentage of patients in the beta group
xperienced in-hospital sustained hypotension and Killip
lass 1, although both groups had equal incidences of
n-hospital bradycardia. We minimized this selection bias
y performing a subgroup analysis on patients without
n-hospital MACE. This analysis showed that even in
atients without in-hospital MACE, those receiving beta-
lockers were less likely to die at six months. In multivariate
nalysis of patients without in-hospital MACE, beta-
lockers were associated with a nonsignificant yet modest
ndependent effect on six-month mortality. The OR of 0.58
n this subset is quite similar to the OR of 0.43 for the entire
opulation. Hence, lack of statistical significance is likely
econdary to fewer patients and fewer events in this sub-
roup.
tudy limitations. Our study has the usual limitations
nherent to retrospective analyses; for example, selection
ias may have led healthier patients to receive beta-blockers.
urther, our results cannot be extrapolated to patients with
igure 3. Multivariate predictors of six-month mortality. CI  confidence
nterval.ardiogenic shock, as the PAMI studies excluded theseatients. Our results may be less representative of contem-
orary practice because of lower rates of glycoprotein
Ib/IIIa and thienopyridine medications and lower stent use
n the PAMI studies. We have no data on the specific
eta-blocker used, the dose employed, or whether adequate
eta-blockade was achieved.
ummary. We have shown that AMI patients receiving
eta-blockers after primary PCI have lower six-month
ortality and MACE. Beta-blockade is independently as-
ociated with reduced six-month mortality, but not MACE.
his benefit is driven by patients with reduced EF or
ulti-vessel CAD.
Our conclusions support the current American College of
ardiology/American Heart Association guidelines recom-
ending beta-blocker therapy for secondary prevention
fter AMI. Whether beta-blockers are necessary after suc-
essful primary PCI for AMI in patients with normal EF or
ingle-vessel CAD is a question that needs to be answered
y future prospective clinical trials.
cknowledgments
he authors thank the people and institutions that partici-
ated in the PAMI trials.
eprint requests and correspondence: Dr. Steven J. Kernis,
illiam Beaumont Hospital Cardiology, 28829 West King Wil-
iam, Farmington Hills, Michigan 48331. E-mail: skernis@
eaumont.edu.
EFERENCES
1. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA
Guidelines for the Management of Patients With Acute Myocardial
Infarction: Executive Summary and Recommendations: a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee on Management of Acute
Myocardial Infarction). Circulation 1999;100:1016–30.
2. Timolol-induced reduction in mortality and reinfarction in patients
surviving acute myocardial infarction. N Engl J Med 1981;304:801–7.
3. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol
trial. Effects on mortality and morbidity in acute myocardial infarction.
Circulation 1983;67:I26–32.
4. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol
after acute myocardial infarction in patients with congestive heart
failure. Circulation 1986;73:503–10.
5. The MIAMI Trial Research Group. Metoprolol In Acute Myocardial
Infarction (MIAMI): a randomised placebo-controlled international
trial. Eur Heart J 1985;6:199–226.
6. First International Study of Infarct Survival Collaborative Group.
Randomised trial of intravenous atenolol among 16 027 cases of
suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57–66.
7. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic
drug therapy in acute myocardial infarction. An overview of results
from randomized controlled trials. JAMA 1993;270:1589–95.
8. Green BK, Gordon GD, Horak AR, Millar RN, Commerford PJ.
Safety of combined intravenous beta-adrenergic blockade (atenolol or
metoprolol) and thrombolytic therapy in acute myocardial infarction.
Am J Cardiol 1992;69:1389–92.
9. Boissel JP, Leizorovicz A, Picolet H, Peyrieux JC. Secondary preven-
tion after high-risk acute myocardial infarction with low-dose acebu-
tolol. Am J Cardiol 1990;66:251–60.
0. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on
mortality among high-risk and low-risk patients after myocardial
infarction. N Engl J Med 1998;339:489–97.
11
1
1
1
1
1
1
1
2
1779JACC Vol. 43, No. 10, 2004 Kernis et al.
May 19, 2004:1773–9 Beta-Blockers After Successful Primary Angioplasty1. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-
blockade after myocardial infarction: systematic review and meta
regression analysis. BMJ 1999;318:1730–7.
2. Harjai KJ, Stone GW, Boura J, et al. Effects of prior beta-blocker
therapy on clinical outcomes after primary coronary angioplasty for
acute myocardial infarction. Am J Cardiol 2003;91:655–60.
3. Stone GW, Brodie BR, Griffin JJ, et al., and the Second Primary
Angioplasty in Myocardial Infarction Trial (PAMI-2) Investigators.
Clinical and angiographic outcomes in patients with previous coronary
artery bypass graft surgery treated with primary balloon angioplasty for
acute myocardial infarction. J Am Coll Cardiol 2000;35:605–11.
4. Stone GW, Marsalese D, Brodie BR, et al. A prospective, randomized
evaluation of prophylactic intraaortic balloon counterpulsation in high
risk patients with acute myocardial infarction treated with primary
angioplasty. Second Primary Angioplasty in Myocardial Infarction
(PAMI-II) Trial Investigators. J Am Coll Cardiol 1997;29:1459–67.
5. Wharton T, Johnston JD, Turco MA, et al. Primary angioplasty for
acute myocardial infarction at hospitals with no surgery on-site: the
prospective PAMI-No SOS Registry (abstr). J Am Coll Cardiol
1998;31:210A.6. Rinfret S, Grines CL, Cosgrove RS, et al., and the Stent-PAMI
Investigators. Quality of life after balloon angioplasty or stenting for
acute myocardial infarction. One-year results from the Stent-PAMI
trial. J Am Coll Cardiol 2001;38:1614–21.
7. Stone GW, Brodie BR, Griffin JJ, et al. Prospective, multicenter study
of the safety and feasibility of primary stenting in acute myocardial
infarction: in-hospital and 30-day results of the PAMI stent pilot trial.
Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Inves-
tigators. J Am Coll Cardiol 1998;31:23–30.
8. Grines CL, Westerhausen DR Jr., Grines LL, et al. A randomized
trial of transfer for primary angioplasty versus on-site thrombolysis in
patients with high-risk myocardial infarction: the Air Primary Angio-
plasty in Myocardial Infarction study. J Am Coll Cardiol 2002;39:
1713–9.
9. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive
heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:
550 –60.
0. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction
in patients with left-ventricular dysfunction: the CAPRICORN ran-
domized trial. Lancet 2001;357:1385–90.
